Tiziana Life Sciences Publishes Positive Foralumab Clinical Data in Peer-Reviewed Neurology Journal

summarizeSummary

Tiziana Life Sciences announced the peer-reviewed publication of positive clinical study results for intranasal foralumab in patients with non-active secondary progressive multiple sclerosis, validating its therapeutic potential.

check_boxKey Events

• Peer-Reviewed Publication

  Clinical study results for intranasal foralumab in non-active secondary progressive multiple sclerosis (na-SPMS) were published in "Neurology Neuroimmunology & Neuroinflammation," a prestigious journal of the American Academy of Neurology.

• Positive Clinical Outcomes

  The open-label study involving ten na-SPMS patients showed stabilization of Expanded Disability Status Scale (EDSS) scores in all patients, with three of four treated for 12 months demonstrating improvement. Fatigue also improved in six out of ten patients.

• Biomarker Validation

  The study revealed significant reductions in microglial activation via TSPO-PET imaging and sustained increases in regulatory T cells (Tregs) and TGFβ expression, supporting the drug's novel mechanism of action.

• Ongoing Phase 2 Trial

  Tiziana is advancing intranasal foralumab in a randomized, double-blind, placebo-controlled Phase 2 trial in na-SPMS, with top-line data anticipated in the first half of 2026.

auto_awesomeAnalysis

The peer-reviewed publication of clinical study results for intranasal foralumab in a prestigious neurology journal provides significant scientific validation for the company's lead candidate. The study demonstrated stabilization of disability, improvement in fatigue, and reduction in neuroinflammation, suggesting a novel mechanism of action. This publication strengthens the scientific credibility of foralumab and supports the ongoing Phase 2 trial, which is expected to report top-line data in the first half of 2026. Investors should monitor the progress of the Phase 2 trial for further clinical advancements.